Complete Phase 3 enrollment for the PREVAIL trial
Delivered after the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 22 Jan 2024
- Due
- 31 Mar 2024
- Delivered
- April 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“1Q 2024: Complete Phase 3 enrollment for PREVAIL”
What we found
Evidence strength B What the grades mean
NewAmsterdam completed Phase 3 PREVAIL trial enrollment in April 2024, after the stated Q1 2024 deadline.
-
B NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter 2026 Financial Results Confirms completion of PREVAIL enrollment with over 9,500 randomized patients in April 2024
-
D NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Company announcement meeting 9,000-patient enrollment target; will extend to end of April 2024
Checked 21 Sep 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Complete
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you NewAmsterdam Pharma Co N.V.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-NAMSW-000037 · Corrections policy